These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 34440488)

  • 1. Molecular Targets for Biological Therapies of Severe Asthma: Focus on Benralizumab and Tezepelumab.
    Cheng SL
    Life (Basel); 2021 Jul; 11(8):. PubMed ID: 34440488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular Targets for Biological Therapies of Severe Asthma.
    Pelaia C; Crimi C; Vatrella A; Tinello C; Terracciano R; Pelaia G
    Front Immunol; 2020; 11():603312. PubMed ID: 33329598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologics in severe asthma.
    Pelaia C; Pelaia G; Crimi C; Longhini F; Lombardo N; Savino R; Sciacqua A; Vatrella A
    Minerva Med; 2022 Feb; 113(1):51-62. PubMed ID: 33555158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mabs for treating asthma: omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab.
    Ridolo E; Pucciarini F; Nizi MC; Makri E; Kihlgren P; Panella L; Incorvaia C
    Hum Vaccin Immunother; 2020 Oct; 16(10):2349-2356. PubMed ID: 32401603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dupilumab and tezepelumab in severe refractory asthma: new opportunities.
    Ragnoli B; Morjaria J; Pignatti P; Montuschi P; Barbieri M; Mondini L; Ruggero L; Trotta L; Malerba M
    Ther Adv Chronic Dis; 2022; 13():20406223221097327. PubMed ID: 35655942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promises and challenges of biologics for severe asthma.
    Tan R; Liew MF; Lim HF; Leung BP; Wong WSF
    Biochem Pharmacol; 2020 Sep; 179():114012. PubMed ID: 32389637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unmet need in severe, uncontrolled asthma: can anti-TSLP therapy with tezepelumab provide a valuable new treatment option?
    Menzies-Gow A; Wechsler ME; Brightling CE
    Respir Res; 2020 Oct; 21(1):268. PubMed ID: 33059715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Current State of Biologic Therapies for Treatment of Refractory Asthma.
    Mavissakalian M; Brady S
    Clin Rev Allergy Immunol; 2020 Oct; 59(2):195-207. PubMed ID: 31981048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pragmatic guide to choosing biologic therapies in severe asthma.
    Kavanagh JE; Hearn AP; Jackson DJ
    Breathe (Sheff); 2021 Dec; 17(4):210144. PubMed ID: 35296105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types.
    Panettieri R; Lugogo N; Corren J; Ambrose CS
    J Asthma Allergy; 2024; 17():219-236. PubMed ID: 38524099
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal Antibodies Targeting Alarmins: A New Perspective for Biological Therapies of Severe Asthma.
    Pelaia C; Pelaia G; Longhini F; Crimi C; Calabrese C; Gallelli L; Sciacqua A; Vatrella A
    Biomedicines; 2021 Aug; 9(9):. PubMed ID: 34572294
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait!
    Bel EH; Ten Brinke A
    Chest; 2017 Dec; 152(6):1276-1282. PubMed ID: 28583618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developments in the Management of Severe Asthma in Children and Adolescents: Focus on Dupilumab and Tezepelumab.
    van Dijk YE; Rutjes NW; Golebski K; Şahin H; Hashimoto S; Maitland-van der Zee AH; Vijverberg SJH
    Paediatr Drugs; 2023 Nov; 25(6):677-693. PubMed ID: 37658954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific Therapy for T2 Asthma.
    Bagnasco D; Testino E; Nicola S; Melissari L; Russo M; Canevari RF; Brussino L; Passalacqua G
    J Pers Med; 2022 Apr; 12(4):. PubMed ID: 35455709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Targeted Therapies for Uncontrolled Asthma.
    Corren J
    J Allergy Clin Immunol Pract; 2019; 7(5):1394-1403. PubMed ID: 31076057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advancements in biologic therapy in eosinophilic asthma.
    Patadia R; Casale TB; Fowler J; Patel S; Cardet JC
    Expert Opin Biol Ther; 2024 Apr; 24(4):251-261. PubMed ID: 38619468
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eosinophilic respiratory disorders and the impact of biologics.
    Bernstein JS; Wechsler ME
    Curr Opin Pulm Med; 2023 May; 29(3):202-208. PubMed ID: 36866734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody therapy for the management of severe asthma with eosinophilic inflammation.
    Ohta K; Nagase H; Suzukawa M; Ohta S
    Int Immunol; 2017 Jul; 29(7):337-343. PubMed ID: 28910970
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized Medicine in Severe Asthma: From Biomarkers to Biologics.
    Chen CY; Wu KH; Guo BC; Lin WY; Chang YJ; Wei CW; Lin MJ; Wu HP
    Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.